Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report

Norihiro Nomura,Takayoshi Ito, Hiroki Shinohara,Nobukazu Shima, Masashi Satou,Dai Sakuma,Junichi Eguchi,Naoyuki Uragami,Yoshio Deguchi,Noboru Yokoyama,Haruhiro Inoue

The Showa University Journal of Medical Sciences（2019）

Cited 0|Views13
No score
Abstract
Hepatocellular carcinoma（HCC）is the sixth most commonly diagnosed cancer worldwide. Sorafenib is an oral multikinase inhibitor used in the palliative treatment of advanced HCC. However, there were no reported cases of complete response（CR）from two previous large phaseⅢ clinical trials. Here, we report a case of CR in a patient with advanced HCC with multiple lymph node and bone metastases, treated with sorafenib monotherapy for 8 months. To our knowledge, this is the first evidence showing CR following sorafenib monotherapy for HCC with bone metastasis.
More
Translated text
Key words
sorafenib monotherapy,advanced hepatocellular carcinoma,hepatocellular carcinoma,bone metastases
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined